Toshiko Ito-Ihara
Specially Appointed Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (20)
Objectives Rituximab (RTX) is a key treatment for ANCA-associated vasculitis (AAV), but RTX-induced acute thrombocytopenia (RIAT) remains a concern. We aimed to evaluate the risk and risk factors of RIAT in patients with AAV undergoing RTX induction therapy. Methods Patients with new-onset microscopic polyangiitis or granulomatosis with polyangiitis who received RTX in a nationwide multicentre registry in Japan were included. RIAT was defined by platelet count reductions within 28 days post-RTX. Risk factors for RIAT were identified by using logistic regression with stepwise selection, and prediction models were developed. Model performance was assessed using C-statistics. Results Among 175 patients with AAV receiving RTX, RIAT occurred in 35.4% of them. Diabetes mellitus (odds ratio [OR] = 4.96), cardiac disease (OR = 3.57), low platelet count (OR = 1.04 per 104/μl decrease), increased serum creatinine (OR = 1.44 per 1 mg/dl increase), low albumin (OR = 2.33 per 1 g/dl decrease), and high KL-6 (OR = 1.09 per 100 U/ml increase) were identified as significant predictors. A predictive model incorporating these factors achieved a C-statistic of 0.817. Conclusion RIAT is a frequent complication of RTX induction in patients with AAV, with diabetes mellitus and cardiac disease being strong risk factors. Our predictive model enables risk assessment for RIAT, allowing clinicians to optimize treatment strategies.
Year:
2026
Year:
2026
Background Bronchiectasis is known to be more frequently observed in patients with microscopic polyangiitis ( MPA ) and granulomatosis with polyangiitis ( GPA ) compared to the general population. However, its association with patient outcomes and the potential influence of immunosuppressive treatment on this association remain unclear. Methods We conducted a multicenter observational study using data from the Japan Collaborative Registry of ANCA ‐Associated Vasculitis (J‐ CANVAS ). Adult patients with newly diagnosed or relapsing MPA or GPA between January 2017 and March 2023 were included. The exposure was clinically apparent bronchiectasis at baseline. Primary outcomes were serious infections and all‐cause mortality; relapses were examined as a secondary outcome over 52 weeks. For each outcome, incidence rate ratios ( IRRs ) were estimated using multivariable Poisson regression models conditioned on confounding factors, incorporating follow‐up time as an offset term. Interactions between initial treatment (prednisone dose, rituximab, cyclophosphamide, intravenous methylprednisolone, and plasma exchange) and bronchiectasis were also evaluated. Results Among 844 patients ( MPA : 614; GPA : 230), 68 (8.1%) had bronchiectasis. During the follow‐up period, there were 122 serious infections among 101 patients, 48 deaths, and 85 relapses among 72 patients. Adjusted IRRs for patients with bronchiectasis were 2.18 (95% CI : 1.25–3.83) for serious infections, 3.07 (1.41–6.66) for mortality, and 1.58 (0.77–3.24) for relapse. No clear interaction was detected between specific treatments and bronchiectasis. Conclusions Bronchiectasis was associated with increased risks of serious infections and mortality in patients with MPA and GPA . However, we did not detect clear interaction by initial treatment, suggesting that avoiding specific therapies may not be necessary.
Year:
2026
Objectives Rituximab (RTX) is a standard maintenance therapy for ANCA-associated vasculitis. Its efficacy in Japan remains unclear, where microscopic polyangiitis (MPA) predominates and clinical characteristics differ from Western-dominated RCT populations. Methods Japanese patients with MPA or granulomatosis with polyangiitis (GPA) enrolled in a nationwide registry were included. Exposure was RTX use during maintenance therapy. The primary endpoint was major relapse-free survival at 104 weeks. The secondary endpoint was any relapse-free survival (major or minor) at 104 weeks. Baseline differences were adjusted using inverse probability of treatment weighting (IPTW) based on key demographic and disease-related covariates. Results A total of 389 patients were analyzed, with 85 in the RTX group. The RTX group included a higher proportion of GPA cases (37/85 vs. 74/304), resulting in baseline imbalance. After IPTW, no major relapses were observed in the RTX group, whereas the major relapse-free survival at 104 weeks was 94.8% in the non-RTX group. The RTX group showed significantly higher any relapse-free survival at 104 weeks (95.4% vs. 83.3%; HR for any relapse, 0.27; 95% CI, 0.09–0.74; p = 0.02). Conclusions Our findings suggest that RTX may be an effective option for remission maintenance in Japanese patients with MPA or GPA.
Year:
2026
Year:
2026
Objectives To evaluate the real-world effectiveness of rituximab (RTX) and intravenous cyclophosphamide (IVCY) compared to non-use for remission induction in microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Methods This observational study emulated a target trial using data from the Japan Collaborative Registry of ANCA-associated Vasculitis. Patients aged ≥20 years with newly diagnosed or relapsing MPA or GPA (2017–23) were included. RTX or IVCY use within 4 weeks defined the treatment group; others formed the control group. The primary outcome was failure to achieve remission at week 24 (Birmingham Vasculitis Activity Score = 0 and prednisolone ≤ 10 mg/day). Secondary outcomes included a composite of death, kidney failure, and relapse, and serious infection. In inverse probability weighted population, risk ratios were estimated using modified Poisson regression. Results Among 544 patients (MPA: 413, GPA: 131), 63.6% received RTX or IVCY. The risk ratio for failure to achieve remission was 0.72 (95% CI: 0.61–0.85), and for the composite outcome was 0.57 (95% CI: 0.33–0.97), and for serious infection was 1.03 (95% CI: 0.47–2.25). Results were robust in sensitivity analyses. Conclusions RTX and IVCY improved short-term outcomes in MPA and GPA without increasing infection risk, supporting their recommendation as standard therapy.
Year:
2026
Objectives To clarify the differences in clinical phenotypes, therapeutic patterns, and outcomes of patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) across geographic regions using a multinational cohort. Methods Data were collected from patients with newly diagnosed or relapsing GPA or MPA in Europe, Japan and the USA from January to July 2020. The composite outcome of kidney failure and/or death within 52 weeks after treatment was evaluated, and the hazard ratios across the regions were estimated using the Cox proportional hazard model. Heterogeneities of the effects were investigated via thorough subgroup analyses. Results Among the 254 eligible patients (Europe, 137; Japan, 73; USA, 44), those in Japan were older and had higher proportions of MPO-ANCA positivity and lung involvement compared with Europe and the USA. The estimated glomerular filtration rate at diagnosis varied across regions, with the highest dialysis requirement in the USA. Cyclophosphamide and rituximab use were, respectively, 57% and 63% in Europe, 29% and 40% in Japan, and 34% and 86% in the USA. Within 52 weeks, 8%, 10% and 18% developed kidney failure, while 9%, 7% and 7% died in Europe, Japan, and the USA, respectively; and the composite outcome occurred in 15%, 14% and 23% of patients. The hazard ratios for kidney failure and/or death were comparable across regions; however, they varied among certain subgroups. Conclusions Although the kidney failure-free survival was comparable across continents, regional differences existed in clinical phenotypes and therapeutic patterns.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Collaborators (13)
Naoto Tamura
Associate Professor
Juntendo University
Nobuyuki Yajima
Professor
Showa University
Shin-ya Kawashiri
Nagasaki University Graduate School of Biomedical Sciences
Tomohisa Uchida
Assistant professor
Nagasaki University Hospital
Yoshia Miyawaki
Special-Appointment Assistant Professor
Okayama Daigaku
Takashi Kawaguchi
Associate Professor
Tokyo University of Pharmacy and Life Sciences
Kazushi Maruo
Associate professor
University of Tsukuba
Takashi Kida
Assistant professor
Kyoto Prefectural University of Medicine
Isao Matsumoto
Professor
University of Tsukuba
Hisashi Noma
Professor
The Institute of Statistical Mathematics
Hiromitsu Asashima
University of Tsukuba
Masaru Shimizu
Specially Appointed Lecturer
University of Tsukuba
Yuya Kondo
Lecturer
University of Tsukuba
Make your next move.
Prepare your application
Review drafts before you send them.